{"id":12301,"date":"2018-12-28T08:41:32","date_gmt":"2018-12-28T13:41:32","guid":{"rendered":"https:\/\/medicarereport.org\/?p=12301"},"modified":"2018-12-28T08:41:32","modified_gmt":"2018-12-28T13:41:32","slug":"3-state-legislative-battles-to-watch-in-2019","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=12301","title":{"rendered":"3 state legislative battles to watch in 2019"},"content":{"rendered":"<p>(By Lev Facher for ST<em>A<\/em>T)<\/p>\n<p><span class=\"big-cap-wrap\"><span class=\"big-cap\">W<\/span><\/span>ASHINGTON \u2014 Drug pricing is on the agenda here in 2019. But with Republicans controlling the Senate and Democrats controlling the House \u2014 and neither party fully on board with the White House\u2019s work on drug pricing \u2014 the next two years are unlikely to be an era of wholesale change for the country\u2019s health care system or how prescription medicines are priced.\u00a0 <a href=\"https:\/\/www.statnews.com\/2018\/12\/28\/3-state-legislative-battles-to-watch\/\">Continue reading article here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre>Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Lev Facher for STAT) WASHINGTON \u2014 Drug pricing is on the agenda here in 2019. But with Republicans controlling<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,20,10],"tags":[],"class_list":["post-12301","post","type-post","status-publish","format-standard","hentry","category-health-care-general","category-health-care-redesign","category-legislative-update"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12301"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12301\/revisions"}],"predecessor-version":[{"id":12302,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/12301\/revisions\/12302"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12301"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12301"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}